Latest revenue
$77.7M
as of 2026-03-31
Latest net income
$34.4M
as of 2026-03-31
Net margin
44.2%
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Fair value · DCF
DCF: 10-year forecast of free cash flow, discounted at the company's WACC, with a Gordon-growth terminal at year 10. FCF is proxied by last fiscal-year net income (proper FCF needs CFO − CapEx by year, which we don't store yet). Drag the slider to test your own growth thesis — the dominant assumption in any DCF is what comes next, not what the math does with it. Beta defaults to 1.0 when not reported.
Community sentiment
Where do you think AUPH is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $2.03B
- Enterprise value
- $1.76B
- P/E (trailing)
- 7.1×
- Forward P/E
- —
- P/B
- 3.58×
- Dividend yield
- 0.0%
- 52-wk high
- $16.88
- 52-wk low
- $7.29
- Beta
- —
- Shares out
- 128.6M
5-year trend
What this company does
Item 1. Business. OVERVIEW Background Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (“LN”). Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor (“BAFF”) and a proliferation-inducing ligand (“APRIL”) for the potential treatment of autoimmune diseases. Net Product Sales Aurinia sells LUPKYNIS to two specialty pharmacies and a specialty distributor in the United States (“U.S.”), and Aurinia sells…
AI summary unavailable — showing raw filing excerpt
Generated from AUPH's filing dated 2026-02-26
Key risks
Item 1A. Risk Factors. An investment in our common shares involves a high degree of risk. You should carefully consider the material risks and uncertainties described below before deciding whether to purchase our common shares. Certain risks may be applicable to multiple categories but are only included once below. In assessing these risks, you should also refer to the other information contained in this Annual Report, including our audited financial statements and related notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Our business, financial condition, results of operations, cash flow, reputation and prospects could be materially and…
AI summary unavailable — showing raw filing excerpt
Generated from AUPH's filing dated 2026-02-26
Profitability
Operating margin
37.1%
1959.4%Net margin
101.5%
4047.7%Return on equity
49.4%
3142.2%Return on assets
38.2%
3558.1%Leverage
Debt / equity
0.29×
36.2%Long-term debt / equity
0.09×
42.0%Debt / assets
22.7%
28.0%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $77.7M | +24.4% | $34.4M | +47.2% | 44.2% |
Q4 2025 2025-12-31 | $77.1M | +28.8% | $210.8M | +1740.0% | 273.4% |
Q3 2025 2025-09-30 | $73.5M | +8.4% | $31.6M | +629.8% | 42.9% |
Q2 2025 2025-06-30 | $70.0M | +22.4% | $21.5M | +2879.6% | 30.7% |
Q1 2025 2025-03-31 | $62.5M | +24.2% | $23.3M | +317.2% | 37.4% |
Q4 2024 2024-12-31 | $59.9M | — | $11.5M | — | 19.1% |
Q3 2024 2024-09-30 | $67.8M | +24.3% | $4.3M | +132.1% | 6.4% |
Q2 2024 2024-06-30 | $57.2M | +37.8% | $722.0K | +106.3% | 1.3% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on AUPH — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$26.3M
Insider selling
$210.0K
Net activity
+$26.1M
Distinct insiders
2
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns AUPH
Institutional value
$315.3M
Total shares held
22.8M
Distinct holders
155
-101 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 7.8M | $116.3M | -82.6K (-1.0%) | Trimmed |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1.3M | $18.6M | — | New |
| 3 | JUPITER ASSET MANAGEMENT LTD | 803.4K | $11.9M | -96.1K (-10.7%) | Trimmed |
| 4 | BNP PARIBAS FINANCIAL MARKETS | 748.8K | $11.1M | +123.1K (+19.7%) | Added |
| 5 | Nuveen, LLC | 653.4K | $9.7M | -11.9K (-1.8%) | Trimmed |
| 6 | Walleye Capital LLC | 643.1K | $9.5M | +620.2K (+2707.8%) | Added |
| 7 | PRUDENTIAL FINANCIAL INC | 590.6K | $8.8M | +218.1K (+58.5%) | Added |
| 8 | JANE STREET GROUP, LLC | 452.1K | $6.7M | -458.6K (-50.4%) | Trimmed |
| 9 | O'SHAUGHNESSY ASSET MANAGEMENT, LLC | 414.0K | $6.1M | +27.2K (+7.0%) | Added |
| 10 | Connor, Clark & Lunn Investment Management Ltd. | 395.4K | $5.9M | +11.8K (+3.1%) | Added |
| 11 | UBS Group AG | 385.9K | $5.7M | +131.2K (+51.5%) | Added |
| 12 | Bank of New York Mellon Corp | 335.8K | $5.0M | +6.4K (+1.9%) | Added |
| 13 | IFP Advisors, Inc | 327.8K | $4.9M | +53.1K (+19.3%) | Added |
| 14 | RITHOLTZ WEALTH MANAGEMENT | 314.4K | $4.7M | +55.6K (+21.5%) | Added |
| 15 | JPMORGAN CHASE & CO | 323.7K | $4.5M | -13.9K (-4.1%) | Trimmed |
| 16 | NORDEA INVESTMENT MANAGEMENT AB | 292.2K | $4.2M | -12.0K (-3.9%) | Trimmed |
| 17 | WELLS FARGO & COMPANY/MN | 275.2K | $4.1M | +10.9K (+4.1%) | Added |
| 18 | LOS ANGELES CAPITAL MANAGEMENT LLC | 274.2K | $4.1M | +150.7K (+122.1%) | Added |
| 19 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 233.3K | $3.5M | +232.8K (+47503.3%) | Added |
| 20 | Swiss National Bank | 220.6K | $3.3M | +0 (+0.0%) | No change |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once AUPH's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.